According to our new research study on "Natural Albumin Market Forecast to 2031 -Global Analysis - by Source, Application, and End User," the market is anticipated to grow from US$ 5.66 billion in 2024 to US$ 8.46 billion by 2031; the market is expected to register a CAGR of 6.0% from 2025 to 2031. The natural albumin Market growth is attributed to the increasing hypoalbuminemia in chronic liver diseases, expanding applications in critical care and surgery, advancements in plasma fractionation technologies, and blood collection infrastructure.

Natural albumin is a water-soluble protein and is the major constituent of blood plasma in humans and animals. It helps to maintain oncotic pressure, transport hormones, vitamins, and drugs, and regulate the fluid balance in the body. It is a pure protein extracted from human serum or an animal source. Natural albumin is a rescue agent in conditions such as hypoalbuminemia, shock, burns, and liver diseases. It is minimally immune-reactive, highly biologically compatible, and strongly biologically functional, which makes it indispensable in therapeutics, diagnostics, and cell culture media. However, issues such as infectious agent transmission and supply shortages have prompted a shift in the demand for safer recombinant products that maintain quality control standards.

The natural albumin Market in North America is segmented into the US, Canada, and Mexico. The growth of the US natural albumin Market can be attributed to the rising prevalence of chronic diseases and advancements in medical applications. According to the Centers for Disease Control and Prevention (CDC), liver disease affected approximately 4.5 million Americans in 2022, and this figure is projected to rise to over 5 million by 2024. This surge creates a greater demand for therapeutic solutions, particularly human serum albumin (HSA), which plays a critical role in managing liver-related conditions. The Canadian Liver Foundation estimated NAFLD prevalence at 25% among adults in 2022-2024 reports, exacerbating hypoalbuminemia risks. New product developments include Health Canada's authorization of Grifols' Albutein 20% extension in 2023 for hypoalbuminemia management, improving serum levels by 40% in trials. Other instances encompass PHAC's 2022-2024 guidelines recommending albumin in refractory sepsis, with 15% reduced mortality in treated patients. These factors, combined with Canada's ageing population and stable plasma collection, sustain demand for natural albumin in clinical practice. The natural albumin market in Mexico is shaped by growing demand for plasma components, a slow but improving donor base, and structural challenges in blood collection. In 2023, Mexico recorded 1.6 million blood donations, according to the The National Blood Transfusion Council (NBTC).

Rising Chronic Kidney Disease (CKD) Prevalence Driving Therapeutic Demand to Provide Market Opportunities in Future

CKD remains a major global health burden: according to the International Society of Nephrology's Global Kidney Health Atlas, approximately 850 million people worldwide suffer from CKD, i.e., roughly 10% of the global population. A meta analysis published in Nephrology Dialysis Transplantation found a global CKD prevalence of 13.0% (2014-2022), with socio economic and demographic disparities. Importantly, low serum albumin (hypoalbuminemia) is associated with worse renal outcomes. A 2023 cohort study in BMC Nephrology showed that when albumin falls below ~4.1 g/dL, patients have faster eGFR decline and higher risk of dialysis initiation. This underscores a direct clinical rationale: increased CKD prevalence means more patients who might benefit from natural albumin therapy to stabilize serum protein levels and slow progression, creating a sustained opportunity for albumin producers.

World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), American Chemical Society Publications, The U.S. Centers for Medicare & Medicaid Services (CMS), US Department of Health & Human Services, Public Health Agency of Canada (PHAC), French National Institute of Health and Medical Research (INSERM), Italian National Institute of Health (ISS), The Korean Journal of Internal Medicine, the Saudi Press Agency (SPA), UAE Ministry of Health and Prevention (MOHAP) are among the primary and secondary sources referred to while preparing the natural albumin Market report.